UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
16.65
-0.11 (-0.66%)
Oct 14, 2025, 4:00 PM EDT - Market closed
UroGen Pharma Revenue
UroGen Pharma had revenue of $24.22M in the quarter ending June 30, 2025, with 10.83% growth. This brings the company's revenue in the last twelve months to $94.24M, up 10.85% year-over-year. In the year 2024, UroGen Pharma had annual revenue of $90.40M with 9.29% growth.
Revenue (ttm)
$94.24M
Revenue Growth
+10.85%
P/S Ratio
8.35
Revenue / Employee
$401,013
Employees
235
Market Cap
770.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
URGN News
- 12 days ago - ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer - GlobeNewsWire
- 5 weeks ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - UroGen Pharma to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - UroGen Pharma: Targeting Profits In 2027 - Seeking Alpha
- 2 months ago - UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 2 months ago - UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 - GlobeNewsWire